View source for CNS5:Medulloblastoma, WNT-activated

{{DISPLAYTITLE:Medulloblastoma, WNT-activated}}

[[CNS5:Table_of_Contents|Central Nervous System Tumours (WHO Classification, 5th ed.)]]

{{Under Construction}}

<span style="color:#0070C0">(''General Instructions – The focus of these pages is the clinically significant genetic alterations in each disease type. This is based on up-to-date knowledge from multiple resources such as PubMed and the WHO classification books. The CCGA is meant to be a supplemental resource to the WHO classification books; the CCGA captures in a continually updated wiki-stye manner the current genetics/genomics knowledge of each disease, which evolves more rapidly than books can be revised and published. If the same disease is described in multiple WHO classification books, the genetics-related information for that disease will be consolidated into a single main page that has this template (other pages would only contain a link to this main page). Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column in a table, click nearby within the table and select the > symbol that appears. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see'' </span><u>''[[Author_Instructions]]''</u><span style="color:#0070C0"> ''and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>].)''</span>
==Primary Author(s)*==

Lisa Lansdon, PhD, Children's Mercy Hospital, University of Missouri–Kansas City

Midhat Farooqi, MD, Children's Mercy Hospital, University of Missouri–Kansas City
==WHO Classification of Disease==

{| class="wikitable"
!Structure
!Disease
|-
|Book
|Central Nervous System Tumours (5th ed.)
|-
|Category
|Embryonal tumours
|-
|Family
|Medulloblastoma
|-
|Type
|Medulloblastomas, molecularly defined
|-
|Subtype(s)
|Medulloblastoma, WNT-activated
|}

==Related Terminology==

{| class="wikitable"
|+
|Acceptable
|N/A
|-
|Not Recommended
|N/A
|}

==Gene Rearrangements==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Details on clinical significance such as prognosis and other important information can be provided in the notes section. Please include references throughout the table. Do not delete the table.'')</span>
{| class="wikitable sortable"
|-
!Driver Gene!!Fusion(s) and Common Partner Genes!!Molecular Pathogenesis!!Typical Chromosomal Alteration(s)
!Prevalence -Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|<span class="blue-text">EXAMPLE:</span> ''ABL1''||<span class="blue-text">EXAMPLE:</span> ''BCR::ABL1''||<span class="blue-text">EXAMPLE:</span> The pathogenic derivative is the der(22) resulting in fusion of 5’ BCR and 3’ABL1.||<span class="blue-text">EXAMPLE:</span> t(9;22)(q34;q11.2)
|<span class="blue-text">EXAMPLE:</span> Common (CML)
|<span class="blue-text">EXAMPLE:</span> D, P, T
|<span class="blue-text">EXAMPLE:</span> Yes (WHO, NCCN)
|<span class="blue-text">EXAMPLE:</span>
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference). BCR::ABL1 is generally favorable in CML (add reference).
|-
|<span class="blue-text">EXAMPLE:</span> ''CIC''
|<span class="blue-text">EXAMPLE:</span> ''CIC::DUX4''
|<span class="blue-text">EXAMPLE:</span> Typically, the last exon of ''CIC'' is fused to ''DUX4''. The fusion breakpoint in ''CIC'' is usually intra-exonic and removes an inhibitory sequence, upregulating ''PEA3'' genes downstream of ''CIC'' including ''ETV1'', ''ETV4'', and ''ETV5''.
|<span class="blue-text">EXAMPLE:</span> t(4;19)(q25;q13)
|<span class="blue-text">EXAMPLE:</span> Common (CIC-rearranged sarcoma)
|<span class="blue-text">EXAMPLE:</span> D
|
|<span class="blue-text">EXAMPLE:</span>

''DUX4'' has many homologous genes; an alternate translocation in a minority of cases is t(10;19), but this is usually indistinguishable from t(4;19) by short-read sequencing (add references).
|-
|<span class="blue-text">EXAMPLE:</span> ''ALK''
|<span class="blue-text">EXAMPLE:</span> ''ELM4::ALK''


Other fusion partners include ''KIF5B, NPM1, STRN, TFG, TPM3, CLTC, KLC1''
|<span class="blue-text">EXAMPLE:</span> Fusions result in constitutive activation of the ''ALK'' tyrosine kinase. The most common ''ALK'' fusion is ''EML4::ALK'', with breakpoints in intron 19 of ''ALK''. At the transcript level, a variable (5’) partner gene is fused to 3’ ''ALK'' at exon 20. Rarely, ''ALK'' fusions contain exon 19 due to breakpoints in intron 18.
|<span class="blue-text">EXAMPLE:</span> N/A
|<span class="blue-text">EXAMPLE:</span> Rare (Lung adenocarcinoma)
|<span class="blue-text">EXAMPLE:</span> T
|
|<span class="blue-text">EXAMPLE:</span>

Both balanced and unbalanced forms are observed by FISH (add references).
|-
|<span class="blue-text">EXAMPLE:</span> ''ABL1''
|<span class="blue-text">EXAMPLE:</span> N/A
|<span class="blue-text">EXAMPLE:</span> Intragenic deletion of exons 2–7 in ''EGFR'' removes the ligand-binding domain, resulting in a constitutively active tyrosine kinase with downstream activation of multiple oncogenic pathways.
|<span class="blue-text">EXAMPLE:</span> N/A
|<span class="blue-text">EXAMPLE:</span> Recurrent (IDH-wildtype Glioblastoma)
|<span class="blue-text">EXAMPLE:</span> D, P, T
|
|
|-
|
|
|
|
|
|
|
|
|}




'''Add content below into table above''' -  
{| class="wikitable sortable"
|-
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
!Diagnostic Significance (Yes, No or Unknown)
!Prognostic Significance (Yes, No or Unknown)
!Therapeutic Significance (Yes, No or Unknown)
!Notes
|-
|''RAP1A::TMIGD3''

1p13.2; 1p13.2
|Unknown
|Unknown
|Rare (estimated ≤5% of medulloblastoma)
|Unknown
|Unknown
|Unknown
|<ref name=":0">{{Cite journal|last=Luo|first=Zaili|last2=Dong|first2=Xinran|last3=Yu|first3=Jianzhong|last4=Xia|first4=Yong|last5=Berry|first5=Kalen P.|last6=Rao|first6=Rohit|last7=Xu|first7=Lingli|last8=Xue|first8=Ping|last9=Chen|first9=Tong|date=2021|title=Genomic and Transcriptomic Analyses Reveals ZNF124 as a Critical Regulator in Highly Aggressive Medulloblastomas|url=https://pubmed.ncbi.nlm.nih.gov/33681213|journal=Frontiers in Cell and Developmental Biology|volume=9|pages=634056|doi=10.3389/fcell.2021.634056|issn=2296-634X|pmc=7930499|pmid=33681213}}</ref>
|-
|''ARID1A::PHACTR4''

1p36.11; 1p35.3
|''ARID1A'' (5’); ''PHACTR4'' (3’)
|Exons 1-4 ''ARID1A''; Exons 11-15 ''PHACTR4''
|Rare (estimated ≤2% of medulloblastoma)
|Unknown
|Unknown
|Unknown
|<ref name=":0" />
| colspan="8" |
|}					


==Individual Region Genomic Gain/Loss/LOH==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene rearrangements. Details on clinical significance such as prognosis and other important information can be provided in the notes section. Can refer to CGC workgroup tables as linked on the homepage if applicable. Please include references throughout the table. Do not delete the table.'') </span>
{| class="wikitable sortable"
|-
!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|<span class="blue-text">EXAMPLE:</span>
7
|<span class="blue-text">EXAMPLE:</span> Loss
|<span class="blue-text">EXAMPLE:</span>
chr7
|<span class="blue-text">EXAMPLE:</span>
Unknown
|<span class="blue-text">EXAMPLE:</span> D, P
|<span class="blue-text">EXAMPLE:</span> No
|<span class="blue-text">EXAMPLE:</span>
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add references).
|-
|<span class="blue-text">EXAMPLE:</span>
8
|<span class="blue-text">EXAMPLE:</span> Gain
|<span class="blue-text">EXAMPLE:</span>
chr8
|<span class="blue-text">EXAMPLE:</span>
Unknown
|<span class="blue-text">EXAMPLE:</span> D, P
|
|<span class="blue-text">EXAMPLE:</span>
Common recurrent secondary finding for t(8;21) (add references).
|-
|<span class="blue-text">EXAMPLE:</span>
17
|<span class="blue-text">EXAMPLE:</span> Amp
|<span class="blue-text">EXAMPLE:</span>
17q12; chr17:39,700,064-39,728,658 [hg38; 28.6 kb]
|<span class="blue-text">EXAMPLE:</span>
''ERBB2''
|<span class="blue-text">EXAMPLE:</span> D, P, T
|
|<span class="blue-text">EXAMPLE:</span>
Amplification of ''ERBB2'' is associated with HER2 overexpression in HER2 positive breast cancer (add references). Add criteria for how amplification is defined.
|-
|
|
|
|
|
|
|
|}



'''Add content below into table above''' -  
·      Monosomy 6 is the most frequently reported genomic alteration, occurring within 80-85% of cases and commonly co-occurring with ''CTNNB1'' somatic mutations<ref name=":6">{{Cite journal|last=Thompson|first=Margaret C.|last2=Fuller|first2=Christine|last3=Hogg|first3=Twala L.|last4=Dalton|first4=James|last5=Finkelstein|first5=David|last6=Lau|first6=Ching C.|last7=Chintagumpala|first7=Murali|last8=Adesina|first8=Adekunle|last9=Ashley|first9=David M.|date=2006-04-20|title=Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations|url=https://pubmed.ncbi.nlm.nih.gov/16567768|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=24|issue=12|pages=1924–1931|doi=10.1200/JCO.2005.04.4974|issn=1527-7755|pmid=16567768}}</ref><ref name=":1">{{Cite journal|last=Northcott|first=Paul A.|last2=Buchhalter|first2=Ivo|last3=Morrissy|first3=A. Sorana|last4=Hovestadt|first4=Volker|last5=Weischenfeldt|first5=Joachim|last6=Ehrenberger|first6=Tobias|last7=Gröbner|first7=Susanne|last8=Segura-Wang|first8=Maia|last9=Zichner|first9=Thomas|date=2017-07-19|title=The whole-genome landscape of medulloblastoma subtypes|url=https://pubmed.ncbi.nlm.nih.gov/28726821|journal=Nature|volume=547|issue=7663|pages=311–317|doi=10.1038/nature22973|issn=1476-4687|pmc=5905700|pmid=28726821}}</ref><ref name=":7">{{Cite journal|last=Clifford|first=Steven C.|last2=Lusher|first2=Meryl E.|last3=Lindsey|first3=Janet C.|last4=Langdon|first4=Jacqueline A.|last5=Gilbertson|first5=Richard J.|last6=Straughton|first6=Debbie|last7=Ellison|first7=David W.|date=2006-11|title=Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis|url=https://pubmed.ncbi.nlm.nih.gov/17172831|journal=Cell Cycle (Georgetown, Tex.)|volume=5|issue=22|pages=2666–2670|doi=10.4161/cc.5.22.3446|issn=1551-4005|pmid=17172831}}</ref><ref name=":2">{{Cite journal|last=Northcott|first=Paul A.|last2=Robinson|first2=Giles W.|last3=Kratz|first3=Christian P.|last4=Mabbott|first4=Donald J.|last5=Pomeroy|first5=Scott L.|last6=Clifford|first6=Steven C.|last7=Rutkowski|first7=Stefan|last8=Ellison|first8=David W.|last9=Malkin|first9=David|date=2019-02-14|title=Medulloblastoma|url=https://pubmed.ncbi.nlm.nih.gov/30765705|journal=Nature Reviews. Disease Primers|volume=5|issue=1|pages=11|doi=10.1038/s41572-019-0063-6|issn=2056-676X|pmid=30765705}}</ref>.

·      With the exception of monosomy 6, this medulloblastoma subtype usually has a balanced genome<ref name=":8">{{Cite journal|last=Northcott|first=Paul A.|last2=Shih|first2=David J. H.|last3=Peacock|first3=John|last4=Garzia|first4=Livia|last5=Morrissy|first5=A. Sorana|last6=Zichner|first6=Thomas|last7=Stütz|first7=Adrian M.|last8=Korshunov|first8=Andrey|last9=Reimand|first9=Jüri|date=2012-08-02|title=Subgroup-specific structural variation across 1,000 medulloblastoma genomes|url=https://pubmed.ncbi.nlm.nih.gov/22832581|journal=Nature|volume=488|issue=7409|pages=49–56|doi=10.1038/nature11327|issn=1476-4687|pmc=3683624|pmid=22832581}}</ref>
{| class="wikitable sortable"
|-
!Chr #!!Gain / Loss / Amp / LOH!!Minimal Region Genomic Coordinates [Genome Build]!!Minimal Region Cytoband
!Diagnostic Significance (Yes, No or Unknown)
!Prognostic Significance (Yes, No or Unknown)
!Therapeutic Significance (Yes, No or Unknown)
!Notes
|-
|6
|Loss
|Chr6:1-170,805,979- [hg38]
|Chr6
|Yes
|Yes – Monosomy 6 is associated with very good outcome in pediatric patients (PDQ)<ref>{{Cite journal|last=Pietsch|first=Torsten|last2=Schmidt|first2=Rene|last3=Remke|first3=Marc|last4=Korshunov|first4=Andrey|last5=Hovestadt|first5=Volker|last6=Jones|first6=David T. W.|last7=Felsberg|first7=Jörg|last8=Kaulich|first8=Kerstin|last9=Goschzik|first9=Tobias|date=2014-07|title=Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort|url=https://pubmed.ncbi.nlm.nih.gov/24791927|journal=Acta Neuropathologica|volume=128|issue=1|pages=137–149|doi=10.1007/s00401-014-1276-0|issn=1432-0533|pmc=4059991|pmid=24791927}}</ref><ref name=":9">{{Cite journal|last=Ellison|first=David W.|last2=Dalton|first2=James|last3=Kocak|first3=Mehmet|last4=Nicholson|first4=Sarah Leigh|last5=Fraga|first5=Charles|last6=Neale|first6=Geoff|last7=Kenney|first7=Anna M.|last8=Brat|first8=Dan J.|last9=Perry|first9=Arie|date=2011-03|title=Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups|url=https://pubmed.ncbi.nlm.nih.gov/21267586|journal=Acta Neuropathologica|volume=121|issue=3|pages=381–396|doi=10.1007/s00401-011-0800-8|issn=1432-0533|pmc=3519926|pmid=21267586}}</ref><ref>{{Cite journal|last=Gajjar|first=Amar|last2=Chintagumpala|first2=Murali|last3=Ashley|first3=David|last4=Kellie|first4=Stewart|last5=Kun|first5=Larry E.|last6=Merchant|first6=Thomas E.|last7=Woo|first7=Shaio|last8=Wheeler|first8=Greg|last9=Ahern|first9=Valerie|date=2006-10|title=Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial|url=https://pubmed.ncbi.nlm.nih.gov/17012043|journal=The Lancet. Oncology|volume=7|issue=10|pages=813–820|doi=10.1016/S1470-2045(06)70867-1|issn=1470-2045|pmid=17012043}}</ref>.
|No<span lang="EN-US">Medulloblastomas,

molecularly defined
|Presence of monosomy 6 is frequently observed, and present in 80-90% of cases<ref name=":1" />.  This finding is much more common in pediatric patients and has been proposed as a marker for WNT subtype α. 


However, absence of monosomy 6 does not rule out the possibility of WNT-activated medulloblastoma<ref name=":1" />.   Furthermore, adult patients will be misdiagnosed if monosomy 6 is used alone as a diagnostic factor, as they cluster within WNT subtype β, which characteristically lacks this finding<ref name=":10">{{Cite journal|last=Cavalli|first=Florence M. G.|last2=Remke|first2=Marc|last3=Rampasek|first3=Ladislav|last4=Peacock|first4=John|last5=Shih|first5=David J. H.|last6=Luu|first6=Betty|last7=Garzia|first7=Livia|last8=Torchia|first8=Jonathon|last9=Nor|first9=Carolina|date=2017-06-12|title=Intertumoral Heterogeneity within Medulloblastoma Subgroups|url=https://pubmed.ncbi.nlm.nih.gov/28609654|journal=Cancer Cell|volume=31|issue=6|pages=737–754.e6|doi=10.1016/j.ccell.2017.05.005|issn=1878-3686|pmc=6163053|pmid=28609654}}</ref>. 


Outside of monosomy 6, other cytogenetic findings are rarely observed in this subtype<ref name=":11">{{Cite journal|last=Northcott|first=Paul A.|last2=Jones|first2=David T. W.|last3=Kool|first3=Marcel|last4=Robinson|first4=Giles W.|last5=Gilbertson|first5=Richard J.|last6=Cho|first6=Yoon-Jae|last7=Pomeroy|first7=Scott L.|last8=Korshunov|first8=Andrey|last9=Lichter|first9=Peter|date=2012-12|title=Medulloblastomics: the end of the beginning|url=https://pubmed.ncbi.nlm.nih.gov/23175120|journal=Nature Reviews. Cancer|volume=12|issue=12|pages=818–834|doi=10.1038/nrc3410|issn=1474-1768|pmc=3889646|pmid=23175120}}</ref>.
|-
| colspan="8" |
|}


==Characteristic Chromosomal or Other Global Mutational Patterns==
<br />
{| class="wikitable sortable"
|-
!Chromosomal Pattern
!Molecular Pathogenesis
!Prevalence - 
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|
|
|
|
|
|
|}
==Gene Mutations (SNV/INDEL)==
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent or common as well either disease defining and/or clinically significant. If a gene has multiple mechanisms depending on the type or site of the alteration, add multiple entries in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity. Details on clinical significance such as prognosis and other important information such as concomitant and mutually exclusive mutations can be provided in the notes section. Please include references throughout the table. Do not delete the table.'') </span>
{| class="wikitable sortable"
|-
!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
Common >20%, Recurrent 5-20% or Rare <5% (Disease)
!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T  
!Established Clinical Significance Per Guidelines - Yes or No (Source)
!Clinical Relevance Details/Other Notes
|-
|<span class="blue-text">EXAMPLE:</span>''EGFR''

<br />
|<span class="blue-text">EXAMPLE:</span> Exon 18-21 activating mutations
|<span class="blue-text">EXAMPLE:</span> Oncogene
|<span class="blue-text">EXAMPLE:</span> Common (lung cancer)
|<span class="blue-text">EXAMPLE:</span> T
|<span class="blue-text">EXAMPLE:</span> Yes (NCCN)
|<span class="blue-text">EXAMPLE:</span> Exons 18, 19, and 21 mutations are targetable for therapy. Exon 20 T790M variants cause resistance to first generation TKI therapy and are targetable by second and third generation TKIs (add references).
|-
|<span class="blue-text">EXAMPLE:</span> ''TP53''; Variable LOF mutations
<br />
|<span class="blue-text">EXAMPLE:</span> Variable LOF mutations
|<span class="blue-text">EXAMPLE:</span> Tumor Supressor Gene
|<span class="blue-text">EXAMPLE:</span> Common (breast cancer)
|<span class="blue-text">EXAMPLE:</span> P
|
|<span class="blue-text">EXAMPLE:</span> >90% are somatic; rare germline alterations associated with Li-Fraumeni syndrome (add reference). Denotes a poor prognosis in breast cancer.
|-
|<span class="blue-text">EXAMPLE:</span> ''BRAF''; Activating mutations
|<span class="blue-text">EXAMPLE:</span> Activating mutations
|<span class="blue-text">EXAMPLE:</span> Oncogene
|<span class="blue-text">EXAMPLE:</span> Common (melanoma)
|<span class="blue-text">EXAMPLE:</span> T
|
|
|-
|
|
|
|
|
|
|
|}Note: A more extensive list of mutations can be found in [https://www.cbioportal.org/ <u>cBioportal</u>], [https://cancer.sanger.ac.uk/cosmic <u>COSMIC</u>], and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.



'''Add content below into table above''' -  
·      Characterized by constitutive activation of the WNT signaling pathway. This occurs in approximately 85-90% of WNT-subtype medulloblastomas via somatic, gain-of-function, mutations in exon 3 of the ''CTNNB1'' gene<ref name=":2" />.

·      Patients without activating ''CTNNB1'' somatic mutations often have germline loss-of-function variants in ''APC'', which then also lead to constitutively increased WNT pathway signaling<ref>{{Cite journal|last=Waszak|first=Sebastian M.|last2=Northcott|first2=Paul A.|last3=Buchhalter|first3=Ivo|last4=Robinson|first4=Giles W.|last5=Sutter|first5=Christian|last6=Groebner|first6=Susanne|last7=Grund|first7=Kerstin B.|last8=Brugières|first8=Laurence|last9=Jones|first9=David T. W.|date=2018-06|title=Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort|url=https://pubmed.ncbi.nlm.nih.gov/29753700|journal=The Lancet. Oncology|volume=19|issue=6|pages=785–798|doi=10.1016/S1470-2045(18)30242-0|issn=1474-5488|pmc=5984248|pmid=29753700}}</ref>

·      The WNT-subtype has the second highest somatic single nucleotide burden of all subgroups with ~1,800 per genome. ''DDX3X'', ''SMARCA4'', ''TP53'', ''CSNK2B'', ''PIK3CA'', and ''EPHA7'' are among the most recurrently mutated genes<ref name=":1" /><ref>{{Cite journal|last=Jones|first=David T. W.|last2=Jäger|first2=Natalie|last3=Kool|first3=Marcel|last4=Zichner|first4=Thomas|last5=Hutter|first5=Barbara|last6=Sultan|first6=Marc|last7=Cho|first7=Yoon-Jae|last8=Pugh|first8=Trevor J.|last9=Hovestadt|first9=Volker|date=2012-08-02|title=Dissecting the genomic complexity underlying medulloblastoma|url=https://pubmed.ncbi.nlm.nih.gov/22832583|journal=Nature|volume=488|issue=7409|pages=100–105|doi=10.1038/nature11284|issn=1476-4687|pmc=3662966|pmid=22832583}}</ref><ref>{{Cite journal|last=Pugh|first=Trevor J.|last2=Weeraratne|first2=Shyamal Dilhan|last3=Archer|first3=Tenley C.|last4=Pomeranz Krummel|first4=Daniel A.|last5=Auclair|first5=Daniel|last6=Bochicchio|first6=James|last7=Carneiro|first7=Mauricio O.|last8=Carter|first8=Scott L.|last9=Cibulskis|first9=Kristian|date=2012-08-02|title=Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations|url=https://pubmed.ncbi.nlm.nih.gov/22820256|journal=Nature|volume=488|issue=7409|pages=106–110|doi=10.1038/nature11329|issn=1476-4687|pmc=3413789|pmid=22820256}}</ref><ref>{{Cite journal|last=Robinson|first=Giles|last2=Parker|first2=Matthew|last3=Kranenburg|first3=Tanya A.|last4=Lu|first4=Charles|last5=Chen|first5=Xiang|last6=Ding|first6=Li|last7=Phoenix|first7=Timothy N.|last8=Hedlund|first8=Erin|last9=Wei|first9=Lei|date=2012-08-02|title=Novel mutations target distinct subgroups of medulloblastoma|url=https://pubmed.ncbi.nlm.nih.gov/22722829|journal=Nature|volume=488|issue=7409|pages=43–48|doi=10.1038/nature11213|issn=1476-4687|pmc=3412905|pmid=22722829}}</ref>
{| class="wikitable sortable"
|-
!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC /  TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
!Diagnostic Significance (Yes, No or Unknown)
!Prognostic Significance (Yes, No or Unknown)
!Therapeutic Significance (Yes, No or Unknown)
!Notes
|-
|''CTNNB1''; Activating;  Exon 3
|Oncogene
|85% (WNT-subtype medulloblastoma cases in COSMIC)
|Often observed with monosomy 6
|''APC''
|Yes
|Yes – Favorable prognosis<ref name=":3">{{Cite journal|last=Surun|first=Aurore|last2=Varlet|first2=Pascale|last3=Brugières|first3=Laurence|last4=Lacour|first4=Brigitte|last5=Faure-Conter|first5=Cécile|last6=Leblond|first6=Pierre|last7=Bertozzi-Salomon|first7=Anne-Isabelle|last8=Berger|first8=Claire|last9=André|first9=Nicolas|date=2020-01-11|title=Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas|url=https://pubmed.ncbi.nlm.nih.gov/31504825|journal=Neuro-Oncology|volume=22|issue=1|pages=128–138|doi=10.1093/neuonc/noz154|issn=1523-5866|pmc=6954432|pmid=31504825}}</ref> 
|No
|~85% of cases<ref name=":1" />; Somatic
|-
|''APC''; 

Loss of Function
|Tumor suppressor
|5-10% (COSMIC)<ref name=":1" />
|
|''CTNNB1''
|
|Yes – Favorable prognosis<ref name=":3" />
|
|Warrant germline evaluation if identified<ref name=":1" /><ref name=":4">{{Cite journal|last=Orr|first=Brent A.|date=2020-05|title=Pathology, diagnostics, and classification of medulloblastoma|url=https://pubmed.ncbi.nlm.nih.gov/32239782|journal=Brain Pathology (Zurich, Switzerland)|volume=30|issue=3|pages=664–678|doi=10.1111/bpa.12837|issn=1750-3639|pmc=7317787|pmid=32239782}}</ref>; LOF of APC  leads to nuclear accumulation of β-catenin, resulting in increased WNT  signaling<ref name=":5">{{Cite journal|last=Khatua|first=Soumen|last2=Song|first2=Anne|last3=Citla Sridhar|first3=Divyaswathi|last4=Mack|first4=Stephen C.|date=2018|title=Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights|url=https://pubmed.ncbi.nlm.nih.gov/29189165|journal=Current Neuropharmacology|volume=16|issue=7|pages=1045–1058|doi=10.2174/1570159X15666171129111324|issn=1875-6190|pmc=6120114|pmid=29189165}}</ref>
|}
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.

==Epigenomic Alterations==

Approximately one third of medulloblastomas across all subgroups carry mutations in histone modifier genes, however, they are not unique to the WNT subtype<ref name=":5" />.

==Genes and Main Pathways Involved==

*Canonical WNT-pathway activation<ref>{{Cite journal|last=Patel|first=Sonal|last2=Alam|first2=Aftab|last3=Pant|first3=Richa|last4=Chattopadhyay|first4=Samit|date=2019|title=Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights|url=https://pubmed.ncbi.nlm.nih.gov/31921137|journal=Frontiers in Immunology|volume=10|pages=2872|doi=10.3389/fimmu.2019.02872|issn=1664-3224|pmc=6927425|pmid=31921137}}</ref>.

{| class="wikitable sortable"
|-
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
|-
|''CTNNB1''; Activating  mutations in exon 3 (especially at amino acid residues p.D32, p.S33, p.G34,  and p.S37; COSMIC, PeCAN)
|Canonical WNT-signaling
|Promotes cell proliferation and differentiation

Promotes immune tolerance

Promotes epithelial-mesenchymal transition 
|-
| colspan="3" |
|}

==Genetic Diagnostic Testing Methods==

*Chromosomes– assess for monosomy 6<ref name=":4" /><ref>{{Cite journal|last=Korshunov|first=Andrey|last2=Chavez|first2=Lukas|last3=Northcott|first3=Paul A.|last4=Sharma|first4=Tanvi|last5=Ryzhova|first5=Marina|last6=Jones|first6=David T. W.|last7=von Deimling|first7=Andreas|last8=Pfister|first8=Stefan M.|last9=Kool|first9=Marcel|date=2017-12|title=DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma|url=https://pubmed.ncbi.nlm.nih.gov/29027579|journal=Acta Neuropathologica|volume=134|issue=6|pages=965–967|doi=10.1007/s00401-017-1776-9|issn=1432-0533|pmid=29027579}}</ref>
*Chromosomal Microarray – assess for monosomy 6
*Sequence analysis (e.g. NGS) – assess for somatic mutations in ''CTNNB1'' and/or ''APC''
*DNA methylation profiling – tumor type and subtype classification by epigenetic signatures
*Transcriptomics – tumor type and subtype classification by gene expression signatures

==Familial Forms==

*Germline variants in ''APC'', which most commonly cause Familial Adenomatous Polyposis, may also lead to the development of WNT-activated subtype medulloblastoma<ref name=":4" /><ref name=":2" />.

==Additional Information==

*DNA methylation profiling is considered to be the current gold-standard for determining MB subgroup and subtype<ref>{{Cite journal|last=Hovestadt|first=Volker|last2=Remke|first2=Marc|last3=Kool|first3=Marcel|last4=Pietsch|first4=Torsten|last5=Northcott|first5=Paul A.|last6=Fischer|first6=Roger|last7=Cavalli|first7=Florence M. G.|last8=Ramaswamy|first8=Vijay|last9=Zapatka|first9=Marc|date=2013-06|title=Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays|url=https://pubmed.ncbi.nlm.nih.gov/23670100|journal=Acta Neuropathologica|volume=125|issue=6|pages=913–916|doi=10.1007/s00401-013-1126-5|issn=1432-0533|pmc=3661908|pmid=23670100}}</ref><ref>{{Cite journal|last=Schwalbe|first=Edward C.|last2=Williamson|first2=Daniel|last3=Lindsey|first3=Janet C.|last4=Hamilton|first4=Dolores|last5=Ryan|first5=Sarra L.|last6=Megahed|first6=Hisham|last7=Garami|first7=Miklós|last8=Hauser|first8=Peter|last9=Dembowska-Baginska|first9=Bożena|date=2013-03|title=DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies|url=https://pubmed.ncbi.nlm.nih.gov/23291781|journal=Acta Neuropathologica|volume=125|issue=3|pages=359–371|doi=10.1007/s00401-012-1077-2|issn=1432-0533|pmc=4313078|pmid=23291781}}</ref> and is available clinically
*Good prognosis is currently thought to be due to alterations in tumour vasculature and its effects on the blood-brain barrier, making the tumor more accessible to systemic chemotherapies<ref>{{Cite journal|last=Phoenix|first=Timothy N.|last2=Patmore|first2=Deanna M.|last3=Boop|first3=Scott|last4=Boulos|first4=Nidal|last5=Jacus|first5=Megan O.|last6=Patel|first6=Yogesh T.|last7=Roussel|first7=Martine F.|last8=Finkelstein|first8=David|last9=Goumnerova|first9=Liliana|date=2016-04-11|title=Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype|url=https://pubmed.ncbi.nlm.nih.gov/27050100|journal=Cancer Cell|volume=29|issue=4|pages=508–522|doi=10.1016/j.ccell.2016.03.002|issn=1878-3686|pmc=4829447|pmid=27050100}}</ref>
*Somatic ''TP53'' mutations do not portend a worse prognosis<ref>{{Cite journal|last=Zhukova|first=Nataliya|last2=Ramaswamy|first2=Vijay|last3=Remke|first3=Marc|last4=Pfaff|first4=Elke|last5=Shih|first5=David J. H.|last6=Martin|first6=Dianna C.|last7=Castelo-Branco|first7=Pedro|last8=Baskin|first8=Berivan|last9=Ray|first9=Peter N.|date=2013-08-10|title=Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma|url=https://pubmed.ncbi.nlm.nih.gov/23835706|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=31|issue=23|pages=2927–2935|doi=10.1200/JCO.2012.48.5052|issn=1527-7755|pmc=4878050|pmid=23835706}}</ref>
*Recent studies employing single-cell RNA-seq<ref>{{Cite journal|last=Hovestadt|first=Volker|last2=Smith|first2=Kyle S.|last3=Bihannic|first3=Laure|last4=Filbin|first4=Mariella G.|last5=Shaw|first5=McKenzie L.|last6=Baumgartner|first6=Alicia|last7=DeWitt|first7=John C.|last8=Groves|first8=Andrew|last9=Mayr|first9=Lisa|date=2019-08|title=Resolving medulloblastoma cellular architecture by single-cell genomics|url=https://pubmed.ncbi.nlm.nih.gov/31341285|journal=Nature|volume=572|issue=7767|pages=74–79|doi=10.1038/s41586-019-1434-6|issn=1476-4687|pmc=6754173|pmid=31341285}}</ref> are revealing transcriptional and genetic heterogeneity within this and other MB subgroups


This disease is <u>defined/characterized</u> as detailed below:

*Medulloblastoma is the most common malignant pediatric brain tumor, though it can also occur in adults<ref name=":11" /><ref name=":5" /><ref>{{Cite journal|last=Ostrom|first=Quinn T.|last2=Gittleman|first2=Haley|last3=Truitt|first3=Gabrielle|last4=Boscia|first4=Alexander|last5=Kruchko|first5=Carol|last6=Barnholtz-Sloan|first6=Jill S.|date=2018-10-01|title=CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015|url=https://pubmed.ncbi.nlm.nih.gov/30445539|journal=Neuro-Oncology|volume=20|issue=suppl_4|pages=iv1–iv86|doi=10.1093/neuonc/noy131|issn=1523-5866|pmc=6129949|pmid=30445539}}</ref>. Recurrent histopathologic, radiologic, and genomic findings have resulted in the establishment of four primary molecularly-defined subgroups: WNT-activated; SHH-activated and ''TP53''-wildtype; SHH-activated and ''TP53''-mutant; and non-WNT/non-SHH<ref name=":12">{{Cite journal|last=Kool|first=Marcel|last2=Korshunov|first2=Andrey|last3=Remke|first3=Marc|last4=Jones|first4=David T. W.|last5=Schlanstein|first5=Maria|last6=Northcott|first6=Paul A.|last7=Cho|first7=Yoon-Jae|last8=Koster|first8=Jan|last9=Schouten-van Meeteren|first9=Antoinette|date=2012-04|title=Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas|url=https://pubmed.ncbi.nlm.nih.gov/22358457|journal=Acta Neuropathologica|volume=123|issue=4|pages=473–484|doi=10.1007/s00401-012-0958-8|issn=1432-0533|pmc=3306778|pmid=22358457}}</ref>. Somatic variants that cause activation of these pathways (e.g., gain-of-function variants in ''CTNNB1'' for the WNT pathway) are considered diagnostic. Of note, a subset of cases can be due to germline loss-of-function variants in the ''APC'' gene (which also result in activation of WNT signaling), which are representative of the spectrum of disorders known as Familial Adenomatous Polyposis (historically referred to as Gardner syndrome; MIM: 175100). In summary, medulloblastoma, WNT-activated, is an embryonal tumor originating in the dorsal brainstem characterized by activation of the WNT signaling pathway.

The <u>epidemiology/prevalence</u> of this disease is detailed below:

*This subtype accounts for approximately 10% of all medulloblastomas<ref name=":8" /><ref name=":11" /><ref name=":12" /><ref name=":13">{{Cite journal|last=Taylor|first=Michael D.|last2=Northcott|first2=Paul A.|last3=Korshunov|first3=Andrey|last4=Remke|first4=Marc|last5=Cho|first5=Yoon-Jae|last6=Clifford|first6=Steven C.|last7=Eberhart|first7=Charles G.|last8=Parsons|first8=D. Williams|last9=Rutkowski|first9=Stefan|date=2012-04|title=Molecular subgroups of medulloblastoma: the current consensus|url=https://pubmed.ncbi.nlm.nih.gov/22134537|journal=Acta Neuropathologica|volume=123|issue=4|pages=465–472|doi=10.1007/s00401-011-0922-z|issn=1432-0533|pmc=3306779|pmid=22134537}}</ref>.
*Most frequently observed in older children (median age 10 years<ref name=":8" /><ref name=":11" />; with a balanced male:female ratio<ref name=":13" />; Of note, this medulloblastoma subtype rarely occurs in infants and rarely metastasizes<ref>{{Cite journal|last=Kumar|first=Rahul|last2=Liu|first2=Anthony P. Y.|last3=Northcott|first3=Paul A.|date=2020-05|title=Medulloblastoma genomics in the modern molecular era|url=https://pubmed.ncbi.nlm.nih.gov/31799776|journal=Brain Pathology (Zurich, Switzerland)|volume=30|issue=3|pages=679–690|doi=10.1111/bpa.12804|issn=1750-3639|pmc=8018047|pmid=31799776}}</ref>
*Excellent prognosis for patients <16 years of age at diagnosis: >95% have a five-year overall survival<ref name=":6" /><ref name=":7" /><ref>{{Cite journal|last=Ellison|first=David W.|last2=Onilude|first2=Olabisi E.|last3=Lindsey|first3=Janet C.|last4=Lusher|first4=Meryl E.|last5=Weston|first5=Claire L.|last6=Taylor|first6=Roger E.|last7=Pearson|first7=Andrew D.|last8=Clifford|first8=Steven C.|last9=United Kingdom Children's Cancer Study Group Brain Tumour Committee|date=2005-11-01|title=beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee|url=https://pubmed.ncbi.nlm.nih.gov/16258095|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=23|issue=31|pages=7951–7957|doi=10.1200/JCO.2005.01.5479|issn=0732-183X|pmid=16258095}}</ref><ref>{{Cite journal|last=Fattet|first=Sarah|last2=Haberler|first2=Christine|last3=Legoix|first3=Patricia|last4=Varlet|first4=Pascale|last5=Lellouch-Tubiana|first5=Arielle|last6=Lair|first6=Severine|last7=Manie|first7=Elodie|last8=Raquin|first8=Marie-Anne|last9=Bours|first9=Danielle|date=2009-05|title=Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics|url=https://pubmed.ncbi.nlm.nih.gov/19197950|journal=The Journal of Pathology|volume=218|issue=1|pages=86–94|doi=10.1002/path.2514|issn=1096-9896|pmid=19197950}}</ref>
*Accounts for ~15% of all adult medulloblastomas, which may have a worse prognosis than pediatric WNT-activated medulloblastoma<ref name=":10" /><ref>{{Cite journal|last=Remke|first=Marc|last2=Hielscher|first2=Thomas|last3=Northcott|first3=Paul A.|last4=Witt|first4=Hendrik|last5=Ryzhova|first5=Marina|last6=Wittmann|first6=Andrea|last7=Benner|first7=Axel|last8=von Deimling|first8=Andreas|last9=Scheurlen|first9=Wolfram|date=2011-07-01|title=Adult medulloblastoma comprises three major molecular variants|url=https://pubmed.ncbi.nlm.nih.gov/21632505|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=29|issue=19|pages=2717–2723|doi=10.1200/JCO.2011.34.9373|issn=1527-7755|pmid=21632505}}</ref><ref>{{Cite journal|last=Clifford|first=Steven C.|last2=Lannering|first2=Birgitta|last3=Schwalbe|first3=Ed C.|last4=Hicks|first4=Debbie|last5=O'Toole|first5=Kieran|last6=Nicholson|first6=Sarah Leigh|last7=Goschzik|first7=Tobias|last8=Zur Mühlen|first8=Anja|last9=Figarella-Branger|first9=Dominique|date=2015-11-17|title=Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial|url=https://pubmed.ncbi.nlm.nih.gov/26420814|journal=Oncotarget|volume=6|issue=36|pages=38827–38839|doi=10.18632/oncotarget.5149|issn=1949-2553|pmc=4770740|pmid=26420814}}</ref><ref>{{Cite journal|last=Zhao|first=Fu|last2=Ohgaki|first2=Hiroko|last3=Xu|first3=Lei|last4=Giangaspero|first4=Felice|last5=Li|first5=Chunde|last6=Li|first6=Peng|last7=Yang|first7=Zhijun|last8=Wang|first8=Bo|last9=Wang|first9=Xingchao|date=2016-07|title=Molecular subgroups of adult medulloblastoma: a long-term single-institution study|url=https://pubmed.ncbi.nlm.nih.gov/27106407|journal=Neuro-Oncology|volume=18|issue=7|pages=982–990|doi=10.1093/neuonc/now050|issn=1523-5866|pmc=4896550|pmid=27106407}}</ref>

The <u>clinical features</u> of this disease are detailed below:

*Cranial and spinal MRI are used for diagnosis<ref name=":2" />
*Signs and symptoms (listed below) can increase in severity over weeks to months
*Signs and symptoms - Headache; Clumsiness; Fatigue; Nausea/vomiting; Declining motor skills and/or ataxia; Vision problems and/or strabismus; Hydrocephalus
*Laboratory findings - None

The <u>sites of involvement</u> of this disease are detailed below:

*Cerebellum, cerebellar peduncle or fourth ventricle<ref name=":4" /><ref>{{Cite journal|last=Patay|first=Z.|last2=DeSain|first2=L. A.|last3=Hwang|first3=S. N.|last4=Coan|first4=A.|last5=Li|first5=Y.|last6=Ellison|first6=D. W.|date=2015-12|title=MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma|url=https://pubmed.ncbi.nlm.nih.gov/26338912|journal=AJNR. American journal of neuroradiology|volume=36|issue=12|pages=2386–2393|doi=10.3174/ajnr.A4495|issn=1936-959X|pmc=4827780|pmid=26338912}}</ref>
*Origin: cells in the extracerebellar lower rhombic lip<ref>{{Cite journal|last=Gibson|first=Paul|last2=Tong|first2=Yiai|last3=Robinson|first3=Giles|last4=Thompson|first4=Margaret C.|last5=Currle|first5=D. Spencer|last6=Eden|first6=Christopher|last7=Kranenburg|first7=Tanya A.|last8=Hogg|first8=Twala|last9=Poppleton|first9=Helen|date=2010-12-23|title=Subtypes of medulloblastoma have distinct developmental origins|url=https://pubmed.ncbi.nlm.nih.gov/21150899|journal=Nature|volume=468|issue=7327|pages=1095–1099|doi=10.1038/nature09587|issn=1476-4687|pmc=3059767|pmid=21150899}}</ref>
*Metastases are much less likely to occur in this subtype relative to other MB subtypes; staging is performed using the Chang classification<ref>{{Cite journal|last=Chang|first=C. H.|last2=Housepian|first2=E. M.|last3=Herbert|first3=C.|date=1969-12|title=An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas|url=https://pubmed.ncbi.nlm.nih.gov/4983156|journal=Radiology|volume=93|issue=6|pages=1351–1359|doi=10.1148/93.6.1351|issn=0033-8419|pmid=4983156}}</ref>

The <u>morphologic features</u> of this disease are detailed below:

*The WNT-activated subgroup is most commonly observed as an embryonal tumor with classic histology located in the cerebellum and/or fourth ventricle<ref name=":4" />
*Cases generally show a classical histologic pattern: Small round blue cell tumor; Sheets of densely packed undifferentiated (embryonal) cells; Individual cells with scant cytoplasm, high nuclear-to-cytoplasmic ratio, and salt-and-pepper chromatin; Presence of mitoses, apoptotic bodies, and Homer Wright rosettes

*High degree of hemorrhage relative to other subtypes
*Rare examples with anaplastic histology have been described<ref name=":9" /><ref>{{Cite journal|last=Kaur|first=Kavneet|last2=Jha|first2=Prerana|last3=Pathak|first3=Pankaj|last4=Suri|first4=Vaishali|last5=Sharma|first5=Mehar Chand|last6=Garg|first6=Ajay|last7=Suri|first7=Ashish|last8=Sarkar|first8=Chitra|date=2019-07|title=Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence in-situ hybridization in resource constrained centres|url=https://pubmed.ncbi.nlm.nih.gov/31104222|journal=Journal of Neuro-Oncology|volume=143|issue=3|pages=393–403|doi=10.1007/s11060-019-03187-y|issn=1573-7373|pmid=31104222}}</ref>
*Activated WNT pathway signaling - commonly visualized by immunohistochemical studies showing nuclear beta-catenin staining

The <u>immunophenotype</u> of this disease is detailed below:

*Majority positive for synaptophysin; INI-1 staining should be retained (positive)
*Molecular subtyping may be performed immunohistochemically using Filamin A, YAP1, GAB1 and beta-catenin<ref name=":9" /><ref name=":4" />

Positive (universal) - Nuclear beta-catenin, Filamin A, and YAP1

Negative (universal) - GAB1

Negative (subset) - YAP1 (in areas of heavy neuronal differentiation)

==Links==

*''[https://pecan.stjude.cloud/proteinpaint/ctnnb1 CTNNB1 entry in PeCAN]''
*''[https://cancer.sanger.ac.uk/cosmic/gene/analysis?coords=AA%3AAA&sn=central_nervous_system&ss=brain&hn=primitive_neuroectodermal_tumour-medulloblastoma&sh=WNT_subtype&wgs=off&id=141847&ln=CTNNB1&start=1&end=782 CTNNB1 entry in COSMIC (WNT-activated medulloblastoma)]''

==References==
<references />
1.      Ellison, DW, Korshunov A, Northcott PA, Taylor MD, Kaur K, Clifford SC. Medulloblastoma, WNT-activated. In: WHO Classification of Tumours Editorial Board. Central nervous system tumours. Lyon (France): International Agency for Research on Cancer; 2021. (WHO classification of tumours series, 5th ed.; vol. 6). <nowiki>https://publications.iarc.fr/601</nowiki>.

2.      PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Cancer Genomics. Bethesda, MD: National Cancer Institute. Updated 12/28/2021. Available at: <nowiki>https://www.cancer.gov/types/childhood-cancers/pediatric-genomics-hp-pdq</nowiki>. Accessed 01/28/2022 [PMID: 27466641]

3.      Khatua S, Song A, Citla Sridhar D, Mack SC. Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. Curr Neuropharmacol. 2018;16(7):1045-1058. doi: 10.2174/1570159X15666171129111324. PMID: 29189165

4.      Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86. doi: 10.1093/neuonc/noy131. Erratum in: Neuro Oncol. 2018 Nov 17. PMID: 30445539

5.      Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomeroy SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec;12(12):818-34. doi: 10.1038/nrc3410. PMID: 23175120

6.      Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A, Cavalli FM, Wang X, Remke M, Wu X, Chiu RY, Chu A, Chuah E, Corbett RD, Hoad GR, Jackman SD, Li Y, Lo A, Mungall KL, Nip KM, Qian JQ, Raymond AG, Thiessen NT, Varhol RJ, Birol I, Moore RA, Mungall AJ, Holt R, Kawauchi D, Roussel MF, Kool M, Jones DT, Witt H, Fernandez-L A, Kenney AM, Wechsler-Reya RJ, Dirks P, Aviv T, Grajkowska WA, Perek-Polnik M, Haberler CC, Delattre O, Reynaud SS, Doz FF, Pernet-Fattet SS, Cho BK, Kim SK, Wang KC, Scheurlen W, Eberhart CG, Fèvre-Montange M, Jouvet A, Pollack IF, Fan X, Muraszko KM, Gillespie GY, Di Rocco C, Massimi L, Michiels EM, Kloosterhof NK, French PJ, Kros JM, Olson JM, Ellenbogen RG, Zitterbart K, Kren L, Thompson RC, Cooper MK, Lach B, McLendon RE, Bigner DD, Fontebasso A, Albrecht S, Jabado N, Lindsey JC, Bailey S, Gupta N, Weiss WA, Bognár L, Klekner A, Van Meter TE, Kumabe T, Tominaga T, Elbabaa SK, Leonard JR, Rubin JB, Liau LM, Van Meir EG, Fouladi M, Nakamura H, Cinalli G, Garami M, Hauser P, Saad AG, Iolascon A, Jung S, Carlotti CG, Vibhakar R, Ra YS, Robinson S, Zollo M, Faria CC, Chan JA, Levy ML, Sorensen PH, Meyerson M, Pomeroy SL, Cho YJ, Bader GD, Tabori U, Hawkins CE, Bouffet E, Scherer SW, Rutka JT, Malkin D, Clifford SC, Jones SJ, Korbel JO, Pfister SM, Marra MA, Taylor MD. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 2;488(7409):49-56. doi: 10.1038/nature11327. PMID: 22832581

7.      Kool M, Korshunov A, Remke M, Jones DT, Schlanstein M, Northcott PA, Cho YJ, Koster J, Schouten-van Meeteren A, van Vuurden D, Clifford SC, Pietsch T, von Bueren AO, Rutkowski S, McCabe M, Collins VP, Bäcklund ML, Haberler C, Bourdeaut F, Delattre O, Doz F, Ellison DW, Gilbertson RJ, Pomeroy SL, Taylor MD, Lichter P, Pfister SM. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012 Apr;123(4):473-84. doi: 10.1007/s00401-012-0958-8. Epub 2012 Feb 23. PMID: 22358457

8.      Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012 Apr;123(4):465-72. doi: 10.1007/s00401-011-0922-z. Epub 2011 Dec 2. PMID: 22134537

9.      Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006 Apr 20;24(12):1924-31. doi: 10.1200/JCO.2005.04.4974. Epub 2006 Mar 27. PMID: 16567768.

10.  Clifford SC, Lusher ME, Lindsey JC, Langdon JA, Gilbertson RJ, Straughton D, Ellison DW. Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle. 2006 Nov;5(22):2666-70. doi: 10.4161/cc.5.22.3446. Epub 2006 Nov 15. PMID: 17172831.

11.  Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC; United Kingdom Children's Cancer Study Group Brain Tumour Committee. beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005 Nov 1;23(31):7951-7. doi: 10.1200/JCO.2005.01.5479. PMID: 16258095.

12.  Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, Lair S, Manie E, Raquin MA, Bours D, Carpentier S, Barillot E, Grill J, Doz F, Puget S, Janoueix-Lerosey I, Delattre O. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol. 2009 May;218(1):86-94. doi: 10.1002/path.2514. PMID: 19197950.

13.  Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nor C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD. Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2017 Jun 12;31(6):737-754.e6. doi: 10.1016/j.ccell.2017.05.005. PMID: 28609654

14.  Remke M, Hielscher T, Northcott PA, Witt H, Ryzhova M, Wittmann A, Benner A, von Deimling A, Scheurlen W, Perry A, Croul S, Kulozik AE, Lichter P, Taylor MD, Pfister SM, Korshunov A. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011 Jul 1;29(19):2717-23. doi: 10.1200/JCO.2011.34.9373. Epub 2011 May 31. PMID: 21632505.

15.  Clifford SC, Lannering B, Schwalbe EC, Hicks D, O'Toole K, Nicholson SL, Goschzik T, Zur Mühlen A, Figarella-Branger D, Doz F, Rutkowski S, Gustafsson G, Pietsch T; SIOP-Europe PNET Group. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget. 2015 Nov 17;6(36):38827-39. doi: 10.18632/oncotarget.5149. PMID: 26420814

16.  Zhao F, Ohgaki H, Xu L, Giangaspero F, Li C, Li P, Yang Z, Wang B, Wang X, Wang Z, Ai L, Zhang J, Luo L, Liu P. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Neuro Oncol. 2016 Jul;18(7):982-90. doi: 10.1093/neuonc/now050. Epub 2016 Apr 21. PMID: 27106407

17.  Northcott PA, Robinson GW, Kratz CP, Mabbott DJ, Pomeroy SL, Clifford SC, Rutkowski S, Ellison DW, Malkin D, Taylor MD, Gajjar A, Pfister SM. Medulloblastoma. Nat Rev Dis Primers. 2019 Feb 14;5(1):11. doi: 10.1038/s41572-019-0063-6. PMID: 30765705.

18.  Orr BA. Pathology, diagnostics, and classification of medulloblastoma. Brain Pathol. 2020 May;30(3):664-678. doi: 10.1111/bpa.12837. PMID: 32239782

19.  Patay Z, DeSain LA, Hwang SN, Coan A, Li Y, Ellison DW. MR Imaging Characteristics of Wingless-Type-Subgroup Pediatric Medulloblastoma. AJNR Am J Neuroradiol. 2015 Dec;36(12):2386-93. doi: 10.3174/ajnr.A4495. Epub 2015 Sep 3. PMID: 26338912

20.  Gibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scoggins M, Ogg R, Pei Y, Yang ZJ, Brun S, Lee Y, Zindy F, Lindsey JC, Taketo MM, Boop FA, Sanford RA, Gajjar A, Clifford SC, Roussel MF, McKinnon PJ, Gutmann DH, Ellison DW, Wechsler-Reya R, Gilbertson RJ. Subtypes of medulloblastoma have distinct developmental origins. Nature. 2010 Dec 23;468(7327):1095-9. doi: 10.1038/nature09587. Epub 2010 Dec 8. PMID: 21150899

21.  Chang CH, Housepian EM, Herbert C Jr. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology. 1969 Dec;93(6):1351-9. doi: 10.1148/93.6.1351. PMID: 4983156.

22.  Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, Kenney AM, Brat DJ, Perry A, Yong WH, Taylor RE, Bailey S, Clifford SC, Gilbertson RJ. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol. 2011 Mar;121(3):381-96. doi: 10.1007/s00401-011-0800-8. Epub 2011 Jan 26. PMID: 21267586

23.  Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, Gröbner S, Segura-Wang M, Zichner T, Rudneva VA, Warnatz HJ, Sidiropoulos N, Phillips AH, Schumacher S, Kleinheinz K, Waszak SM, Erkek S, Jones DTW, Worst BC, Kool M, Zapatka M, Jäger N, Chavez L, Hutter B, Bieg M, Paramasivam N, Heinold M, Gu Z, Ishaque N, Jäger-Schmidt C, Imbusch CD, Jugold A, Hübschmann D, Risch T, Amstislavskiy V, Gonzalez FGR, Weber UD, Wolf S, Robinson GW, Zhou X, Wu G, Finkelstein D, Liu Y, Cavalli FMG, Luu B, Ramaswamy V, Wu X, Koster J, Ryzhova M, Cho YJ, Pomeroy SL, Herold-Mende C, Schuhmann M, Ebinger M, Liau LM, Mora J, McLendon RE, Jabado N, Kumabe T, Chuah E, Ma Y, Moore RA, Mungall AJ, Mungall KL, Thiessen N, Tse K, Wong T, Jones SJM, Witt O, Milde T, Von Deimling A, Capper D, Korshunov A, Yaspo ML, Kriwacki R, Gajjar A, Zhang J, Beroukhim R, Fraenkel E, Korbel JO, Brors B, Schlesner M, Eils R, Marra MA, Pfister SM, Taylor MD, Lichter P. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017 Jul 19;547(7663):311-317. doi: 10.1038/nature22973. PMID: 28726821

24.  Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, Grund KB, Brugières L, Jones DTW, Pajtler KW, Morrissy AS, Kool M, Sturm D, Chavez L, Ernst A, Brabetz S, Hain M, Zichner T, Segura-Wang M, Weischenfeldt J, Rausch T, Mardin BR, Zhou X, Baciu C, Lawerenz C, Chan JA, Varlet P, Guerrini-Rousseau L, Fults DW, Grajkowska W, Hauser P, Jabado N, Ra YS, Zitterbart K, Shringarpure SS, De La Vega FM, Bustamante CD, Ng HK, Perry A, MacDonald TJ, Hernáiz Driever P, Bendel AE, Bowers DC, McCowage G, Chintagumpala MM, Cohn R, Hassall T, Fleischhack G, Eggen T, Wesenberg F, Feychting M, Lannering B, Schüz J, Johansen C, Andersen TV, Röösli M, Kuehni CE, Grotzer M, Kjaerheim K, Monoranu CM, Archer TC, Duke E, Pomeroy SL, Shelagh R, Frank S, Sumerauer D, Scheurlen W, Ryzhova MV, Milde T, Kratz CP, Samuel D, Zhang J, Solomon DA, Marra M, Eils R, Bartram CR, von Hoff K, Rutkowski S, Ramaswamy V, Gilbertson RJ, Korshunov A, Taylor MD, Lichter P, Malkin D, Gajjar A, Korbel JO, Pfister SM. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 Jun;19(6):785-798. doi: 10.1016/S1470-2045(18)30242-0. Epub 2018 May 9. PMID: 29753700

25.  Jones DT, Jäger N, Kool M, Zichner T, Hutter B, Sultan M, Cho YJ, Pugh TJ, Hovestadt V, Stütz AM, Rausch T, Warnatz HJ, Ryzhova M, Bender S, Sturm D, Pleier S, Cin H, Pfaff E, Sieber L, Wittmann A, Remke M, Witt H, Hutter S, Tzaridis T, Weischenfeldt J, Raeder B, Avci M, Amstislavskiy V, Zapatka M, Weber UD, Wang Q, Lasitschka B, Bartholomae CC, Schmidt M, von Kalle C, Ast V, Lawerenz C, Eils J, Kabbe R, Benes V, van Sluis P, Koster J, Volckmann R, Shih D, Betts MJ, Russell RB, Coco S, Tonini GP, Schüller U, Hans V, Graf N, Kim YJ, Monoranu C, Roggendorf W, Unterberg A, Herold-Mende C, Milde T, Kulozik AE, von Deimling A, Witt O, Maass E, Rössler J, Ebinger M, Schuhmann MU, Frühwald MC, Hasselblatt M, Jabado N, Rutkowski S, von Bueren AO, Williamson D, Clifford SC, McCabe MG, Collins VP, Wolf S, Wiemann S, Lehrach H, Brors B, Scheurlen W, Felsberg J, Reifenberger G, Northcott PA, Taylor MD, Meyerson M, Pomeroy SL, Yaspo ML, Korbel JO, Korshunov A, Eils R, Pfister SM, Lichter P. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 2;488(7409):100-5. doi: 10.1038/nature11284. PMID: 22832583

26.  Kumar R, Liu APY, Northcott PA. Medulloblastoma genomics in the modern molecular era. Brain Pathol. 2020 May;30(3):679-690. doi: 10.1111/bpa.12804. Epub 2019 Dec 16. PMID: 31799776

27.  Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, Ramos AH, Ross MG, Russ C, Shefler E, Sivachenko A, Sogoloff B, Stojanov P, Tamayo P, Mesirov JP, Amani V, Teider N, Sengupta S, Francois JP, Northcott PA, Taylor MD, Yu F, Crabtree GR, Kautzman AG, Gabriel SB, Getz G, Jäger N, Jones DT, Lichter P, Pfister SM, Roberts TM, Meyerson M, Pomeroy SL, Cho YJ. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 2;488(7409):106-10. doi: 10.1038/nature11329. PMID: 22820256

28.  Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, Phoenix TN, Hedlund E, Wei L, Zhu X, Chalhoub N, Baker SJ, Huether R, Kriwacki R, Curley N, Thiruvenkatam R, Wang J, Wu G, Rusch M, Hong X, Becksfort J, Gupta P, Ma J, Easton J, Vadodaria B, Onar-Thomas A, Lin T, Li S, Pounds S, Paugh S, Zhao D, Kawauchi D, Roussel MF, Finkelstein D, Ellison DW, Lau CC, Bouffet E, Hassall T, Gururangan S, Cohn R, Fulton RS, Fulton LL, Dooling DJ, Ochoa K, Gajjar A, Mardis ER, Wilson RK, Downing JR, Zhang J, Gilbertson RJ. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012 Aug 2;488(7409):43-8. doi: 10.1038/nature11213. PMID: 22722829

29.  Korshunov A, Chavez L, Northcott PA, Sharma T, Ryzhova M, Jones DTW, von Deimling A, Pfister SM, Kool M. DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. Acta Neuropathol. 2017 Dec;134(6):965-967. doi: 10.1007/s00401-017-1776-9. Epub 2017 Oct 13. PMID: 29027579

30.  Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, Wadhwa E, Cho YJ, Stewart CF, Gilbertson RJ. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell. 2016 Apr 11;29(4):508-522. doi: 10.1016/j.ccell.2016.03.002. Epub 2016 Mar 31. PMID: 27050100

31.  Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister SM. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol. 2010 Jun 20;28(18):3054-60. doi: 10.1200/JCO.2009.25.7121. Epub 2010 May 17. PMID: 20479417.

32.  Goschzik T, Schwalbe EC, Hicks D, Smith A, Zur Muehlen A, Figarella-Branger D, Doz F, Rutkowski S, Lannering B, Pietsch T, Clifford SC. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial. Lancet Oncol. 2018 Dec;19(12):1602-1616. doi: 10.1016/S1470-2045(18)30532-1. Epub 2018 Nov 1. PMID: 30392813

33.  Hovestadt V, Smith KS, Bihannic L, Filbin MG, Shaw ML, Baumgartner A, DeWitt JC, Groves A, Mayr L, Weisman HR, Richman AR, Shore ME, Goumnerova L, Rosencrance C, Carter RA, Phoenix TN, Hadley JL, Tong Y, Houston J, Ashmun RA, DeCuypere M, Sharma T, Flasch D, Silkov A, Ligon KL, Pomeroy SL, Rivera MN, Rozenblatt-Rosen O, Rusert JM, Wechsler-Reya RJ, Li XN, Peyrl A, Gojo J, Kirchhofer D, Lötsch D, Czech T, Dorfer C, Haberler C, Geyeregger R, Halfmann A, Gawad C, Easton J, Pfister SM, Regev A, Gajjar A, Orr BA, Slavc I, Robinson GW, Bernstein BE, Suvà ML, Northcott PA. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 Aug;572(7767):74-79. doi: 10.1038/s41586-019-1434-6. Epub 2019 Jul 24. PMID: 31341285

34.  Zhukova N, Ramaswamy V, Remke M, Pfaff E, Shih DJ, Martin DC, Castelo-Branco P, Baskin B, Ray PN, Bouffet E, von Bueren AO, Jones DT, Northcott PA, Kool M, Sturm D, Pugh TJ, Pomeroy SL, Cho YJ, Pietsch T, Gessi M, Rutkowski S, Bognar L, Klekner A, Cho BK, Kim SK, Wang KC, Eberhart CG, Fevre-Montange M, Fouladi M, French PJ, Kros M, Grajkowska WA, Gupta N, Weiss WA, Hauser P, Jabado N, Jouvet A, Jung S, Kumabe T, Lach B, Leonard JR, Rubin JB, Liau LM, Massimi L, Pollack IF, Shin Ra Y, Van Meir EG, Zitterbart K, Schüller U, Hill RM, Lindsey JC, Schwalbe EC, Bailey S, Ellison DW, Hawkins C, Malkin D, Clifford SC, Korshunov A, Pfister S, Taylor MD, Tabori U. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10;31(23):2927-35. doi: 10.1200/JCO.2012.48.5052. Epub 2013 Jul 8. PMID: 23835706

35.  Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R, Cavalli FM, Ramaswamy V, Zapatka M, Reifenberger G, Rutkowski S, Schick M, Bewerunge-Hudler M, Korshunov A, Lichter P, Taylor MD, Pfister SM, Jones DT. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol. 2013 Jun;125(6):913-6. doi: 10.1007/s00401-013-1126-5. Epub 2013 May 14. PMID: 23670100

36.  Schwalbe EC, Williamson D, Lindsey JC, Hamilton D, Ryan SL, Megahed H, Garami M, Hauser P, Dembowska-Baginska B, Perek D, Northcott PA, Taylor MD, Taylor RE, Ellison DW, Bailey S, Clifford SC. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 2013 Mar;125(3):359-71. doi: 10.1007/s00401-012-1077-2. Epub 2013 Jan 5. PMID: 23291781

37.  Surun A, Varlet P, Brugières L, Lacour B, Faure-Conter C, Leblond P, Bertozzi-Salomon AI, Berger C, André N, Sariban E, Raimbault S, Prieur F, Desseigne F, Zattara H, Guimbaud R, Polivka M, Delisle MB, Vasiljevic A, Maurage CA, Figarella-Branger D, Coulet F, Guerrini-Rousseau L, Alapetite C, Dufour C, Colas C, Doz F, Bourdeaut F. Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas. Neuro Oncol. 2020 Jan 11;22(1):128-138. doi: 10.1093/neuonc/noz154. PMID: 31504825

==Notes==


<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the [[Leadership|''<u>Associate Editor</u>'']] or other CCGA representative.  When pages have a major update, the new author will be acknowledged at the beginning of the page, and those who contributed previously will be acknowledged below as a prior author. 

Prior Author(s):
<nowiki>*</nowiki>''Citation of this Page'': “Medulloblastoma, WNT-activated”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/CNS5:Medulloblastoma, WNT-activated</nowiki>.
[[Category:CNS5]]
[[Category:DISEASE]]
[[Category:Diseases M]]